Gilead Sciences 4Q and FY 2006: Product sales.

(From Chemical Business NewsBase - Company Reports - CBNB)

Gilead Sciences Inc has reported on product sales for its 4Q and FY 2006 (period ends 31 Dec 2006). Product sales were a record $768.1 M for 4Q 2006, up 56% over the same period in 2005, marking more than three years of consecutive quarterly product sales growth. For fiscal 2006, product sales were $2.59 bn compared to $1.81 bn in 2005. This growth continued to be driven primarily by Gilead's HIV product franchise, including the strong uptake of Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) following its launch in Jul 2006 in the US, and continued strong performance of …